GLP1R and metabolic dysfunction-associated steatotic liver disease: In particular, although there are no licensed treatments for NAFLD, three different classes of glucose-lowering drugs (peroxisome proliferator-activated receptor agonists, GLP-1 receptor agonists and SGLT-2 inhibitors) showed promise in the treatment of this common liver disease.